Advances in Therapy
October 14, 2026
Ahmed I Anwar, Abdul-Rahman A Hegazi, M Farris Sawaya et al.
Substance use disorders (SUDs) are a major global health burden, and psychedelic-assisted therapies are now gaining scientific interest, with ibogaine being considered as a candidate for anti-addictive effects across multiple substance classes. Ibogaine is a multi-target indole alkaloid acting on opioid, glutamatergic, serotonergic, and sigma systems with potential to rapidly reduce withdrawal...
Asian Journal of Psychiatry
October 12, 2026
Gia Han Le, Sabrina Wong, Simryn Selby et al.
Ketamine is a rapid-acting antidepressant with demonstrated efficacy in major depressive disorder and treatment-resistant depression, yet the mechanisms by which its molecular actions translate into sustained clinical improvement remain incompletely understood. Prevailing models have emphasized N-methyl-D-aspartate receptor antagonism and downstream glutamatergic signaling; however, convergent...
Surgical Neurology International
October 9, 2026
Andrea Garcia-Bitar, Eduardo Jesus Castañeda, José Rafael Buenrostro-Rangel et al.
Background: Neurosurgical patients carry a high and frequently undertreated burden of psychological suffering, acute and chronic pain, and neurological deficits amenable to recovery. The resurgence of psychedelic research has produced relevant evidence in adjacent fields, but its applicability to neurosurgery has not been systematized. This review synthesizes that evidence across prevention,...
Therapeutic Advances in Psychopharmacology
October 8, 2026
Gianluca A. Florineth, Anna L. Boeker, Felix Müller et al.
Background Classic psychedelics show potential for treating psychiatric disorders, yet the psychological framework of psychedelic-assisted therapy (PAT) remains underspecified. As regulatory approval approaches, defining the contribution of psychological interventions to clinical outcomes is critical for both mechanism inference and implementation. Objectives To systematically review the...
Molecular Psychiatry
October 3, 2026
Xiubo Du, Feiyuan Peng, Xiaohui Wang
Disorders of consciousness (DoC), including coma, unresponsive wakefulness syndrome (also known as vegetative state), and minimally conscious state, represent profound disruptions in awareness and responsiveness due to severe brain injury, with limited therapeutic options available. Recent advancements in neuroimaging have improved our ability to detect residual brain activity in DoC patients,...
Psychedelics
October 1, 2026
David S. Mathai, Brian Pilecki, Hadi Zaki et al.
In 2019, the U.S. Food and Drug Administration (FDA) approved a patented formulation and delivery method of esketamine, the S-enantiomer of ketamine, for patients with treatment-resistant depression (TRD). While ketamine-based treatments share similarities with serotonin 2 A receptor-mediated “classic psychedelics” like psilocybin regarding subjective drug effects and stimulation of...
Journal of Neuroendocrinology
October 1, 2026
Cristian Ferreira Corona, Felipe Alves Alencar Lima, Jessica Sabrina Canedo da Silva Sumensse et al.
Abstract Human binge eating disorder is characterized by recurrent episodes of excessive food consumption accompanied by loss of control and is strongly associated with alterations in reward processing and emotional regulation. Ayahuasca, a psychoactive botanical preparation traditionally used in Amazonian medicine, has been shown to modulate serotonergic signaling and reward‐related behaviors...
Frontiers in Pharmacology
September 30, 2026
Kacper Żełabowski, Tomasz Wieczorek, Adam Hamed
Stroboscopic light stimulation (SLS) and psilocybin each induce altered states whose phenomenology and neurophysiology partly overlap, including posterior alpha-band changes and visual imagery. The two states engage the alpha band through different operations - pharmacological suppression under psilocybin and frequency-selective visual drive under SLS. We formalize their possible interaction...
Translational Psychiatry
September 28, 2026
Johan Saelens, Franziska Stadler, Victoria Forschauer et al.
Obsessive-compulsive disorder (OCD) is a highly debilitating and often chronic condition. A large percentage of patients do not respond to first-line treatments with selective serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy (CBT), underscoring the need for novel therapeutic approaches. In this context, promising innovative treatments have recently emerged for OCD; these...
International Journal of Innovative Technologies in Social Science
September 28, 2026
Klaudia Karolina Wójcik, Michal Kieres, Krzysztof Sebastian Habirek et al.
The article aims to compare receptor mechanisms related to neurotransmitters for some of the most widely used psychoactive substances - amphetamine, cocaine, ecstasy (MDMA), and psilocybin - and to link these mechanisms to cardiovascular effects, thermoregulation, and neurotoxicity. The review is based mainly on in vitro studies on transporters and receptors, animal models, and controlled...